NCT01783873

Brief Summary

Occupational asthma (OA) caused by high molecular weight (HMW) substances have been shown to induce predominantly an eosinophilic inflammation. In contrast, OA caused by low molecular weight (LMW) substances results in a neutrophilic inflammation. In addition, data regarding phenotype of lymphocytes in OA caused by HMW and LMW substances are scarce. The use of a new equipment will allow the realization of specific standardized bronchial challenges (BC) to occupational agents. Thus, we propose to study in more detail the cellular mechanisms involved during BC to HMW and LMW occupational agents in a double-blind placebo controlled study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 28, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 5, 2013

Completed
6.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2019

Completed
Last Updated

June 29, 2020

Status Verified

August 1, 2019

Enrollment Period

7.3 years

First QC Date

January 28, 2013

Last Update Submit

June 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Assessment of cellular inflammation in peripheral blood and induced sputum

    Before and after bronchial challenge: assessment of cellular inflammation in peripheral blood and induced sputum, exhaled NO; assessment of peripheral T lymphocyte phenotype.

    33 months

Study Arms (2)

Placebo

PLACEBO COMPARATOR
Other: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)

flour allergen extract or quaternary ammonium compound

ACTIVE COMPARATOR
Other: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)

Interventions

At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.

Placeboflour allergen extract or quaternary ammonium compound

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • For patients with occupational asthma to wheat flour:
  • Clinical history,
  • A positive skin test to wheat flour and / or specific IgE to wheat flour
  • For patients with occupational asthma to quaternary ammonium compounds:
  • Clinical history,
  • For two types of asthma:
  • Patients must have a worsening of bronchial hyperreactivity during work compared to a rest period assessed by a metacholine challenge
  • FEV before challenge (nonspecific and specific) must be\> 70%.

You may not qualify if:

  • Asthmas:
  • no occupational asthma:
  • secondary to clinically relevant sensitization to an allergen domestic
  • aggravated at work.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpitaux Universitaires de Strasbourg

Strasbourg, 67091, France

Location

MeSH Terms

Conditions

Asthma, Occupational

Condition Hierarchy (Ancestors)

AsthmaBronchial DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesOccupational Diseases

Study Officials

  • Frédéric De BLAY, MD

    University Hospital, Strasbourg, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2013

First Posted

February 5, 2013

Study Start

September 1, 2012

Primary Completion

December 12, 2019

Study Completion

December 12, 2019

Last Updated

June 29, 2020

Record last verified: 2019-08

Locations